Loading...

MEK inhibition increases lapatinib sensitivity via modulation of FOXM1

The standard targeted therapy for HER2-overexpressing breast cancer is the HER2 monoclonal antibody, trastuzumab. Although effective, many patients eventually develop trastuzumab resistance. The dual EGFR/HER2 small molecule tyrosine kinase inhibitor lapatinib is approved for use in trastuzumab-refr...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Gayle, Sylvia S., Castellino, Robert C., Buss, Meghan C., Nahta, Rita
Format: Artigo
Sprog:Inglês
Udgivet: 2013
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3650616/
https://ncbi.nlm.nih.gov/pubmed/23531216
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!